PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK.\', \'Biopharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.\', \'Pall Europe, Portsmouth, UK.\', \'Sartorius Stedim Biotech GmbH, Goettingen, Germany.\', \'Sartorius Stedim Switzerland AG, Tagelswangen, Switzerland.\', \'Vaccine Manufacturing and Innovation Centre, Oxford, UK.\', \'Cobra Biologics, Keele, UK.\', \'Halix BV, Leiden, The Netherlands.\', \'Oxford Biomedica PLC, Cowley, UK.\', \'Clinical Biomanufacturing Facility, Nuffield Department of Medicine, University of Oxford, Oxford, UK.\', \'Purification Process Sciences, Biopharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/bit.27945
?:hasPublicationType
?:journal
  • Biotechnology and bioengineering
is ?:pmid of
?:pmid
?:pmid
  • 34585736
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 165
?:title
  • Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34585736>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34585736>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all